Villar Isabel, Izuel Monica, Carrizo Santiago, Vicente Eugenio, Marin Jose M
Pharmacy Services, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Sleep. 2009 May;32(5):623-8. doi: 10.1093/sleep/32.5.623.
The aim of this study was to compare 2 groups of patients with severe obstructive sleep apnea (OSA) who were taking medication for cardiovascular disease: those who were compliant with nasal continuous positive airway pressure (CPAP) treatment and those who refused treatment or were noncompliant with CPAP treament.
In a cohort of 2158 patients with severe OSA (apnea-hypopnea index >30) a 2-year prospective longitudinal assessment of adherence and persistence with 3 medication categories (antihypertensives, statins, and antiplatelets) was carried out using the administrative database of the National Health Service. Medication adherence was evaluated by calculating the medication possession ratio (%MPR = days supplylactual days to refill x 100) for each drug. Medication persistency was defined as the proportion of subjects having filled a prescription in the last 30 days of the 2-year period. CPAP use was assessed at every follow-up visit after the treatment was prescribed. Medication adherence was compared between patients who had adequate CPAP adherence (> 4 h/day) and those who declined CPAP therapy or had discontinued CPAP due to an average use of less than 4 hours per day.
The average 2-year MPR for antihypertensives, statins, and antiplatelets was not different among patients who used CPAP (88%, 81%, 95%) or did not use CPAP (86%, 77%, 93%). Female sex and increased number of comorbidities were predictors of good medication adherence (MPR > 80%). The rates of persistence for the 3 studied medications after the 2-year observation period were not different between the 2 groups (patients with or without CPAP).
Medication adherence and persistence during a 2-year period for 3 well-known protective cardiovascular medications were not different in patients with severe OSA, whether or not they were treated with CPAP.
本研究旨在比较两组患有严重阻塞性睡眠呼吸暂停(OSA)且正在服用心血管疾病药物的患者:一组为依从鼻持续气道正压通气(CPAP)治疗的患者,另一组为拒绝治疗或不依从CPAP治疗的患者。
在一个包含2158例严重OSA患者(呼吸暂停低通气指数>30)的队列中,利用国民医疗服务体系的管理数据库对3类药物(抗高血压药、他汀类药物和抗血小板药)的依从性和持续性进行了为期2年的前瞻性纵向评估。通过计算每种药物的药物持有率(%MPR = 供应天数/实际再填充天数×100)来评估药物依从性。药物持续性定义为在2年期间最后30天内开过处方的受试者比例。在开出CPAP治疗处方后的每次随访中评估CPAP的使用情况。比较了CPAP依从性良好(>4小时/天)的患者与拒绝CPAP治疗或因平均每天使用少于4小时而停用CPAP的患者之间的药物依从性。
使用CPAP的患者(88%、81%、95%)和未使用CPAP的患者(86%、77%、93%)在抗高血压药、他汀类药物和抗血小板药方面的平均2年MPR没有差异。女性和合并症数量增加是良好药物依从性(MPR>80%)的预测因素。两组(使用或未使用CPAP的患者)在2年观察期后3种研究药物的持续性率没有差异。
对于严重OSA患者,无论是否接受CPAP治疗,3种知名的心血管保护药物在2年期间的药物依从性和持续性没有差异。